Physician Sentiment on LYNPARZA®

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated 2026-07-14. KOL Pulse reports the physician conversation and does not endorse any product.

Trial 1 · NCT02032823

What do oncologists think of the OlympiA trial (LYNPARZA®)?

OlympiA — Adjuvant gBRCAm, HER2-negative, high-risk early breast cancer (1 year of olaparib)

FDA APPROVED · Mar 2022FDA-approved March 11, 2022, for the adjuvant treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy; patients are selected by an FDA-approved companion diagnostic.

Physicians are broadly favorable, with real nuance on OlympiA: 0% of 13 verified physician voices positive, 0% nuanced (praising the result while flagging a caveat), 100% neutral, 0% critical.

100%

Positive 0% Nuanced 0% Neutral 100% Critical 0%

Denominator: 13 distinct verified physician voices across 18 oncologist posts, 2024-12-11 to 2024-12-11. Sponsor: NRG Oncology / Breast International Group (funded by AstraZeneca & Merck)

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT02032823 · NEJM 2021 — OlympiA primary publication

Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021;384(25):2394-2405.

Physician voices — verbatim

Full physician voice list (13)

Physician	Comment (verbatim)	Sentiment	Impressions
Sara Tolaney @stolaney1	OlympiA update, median f/u 6.1 yrs presented by @judygarber5 iDFS: TNBC: HR 0.65, HR 0.68 OS ITT: 0.72 Fewer new primary cancers seen in olaparib arm; no evidence of increased risk of MDS or AML @SABCSSanAntonio @OncoAlert #SABCS24	Neutral	3,947
Stephanie Graff, MD, FACP, FASCO @DrSGraff	10 year follow up on OlympiA shows persistent benefit in iDFS, OS. #SABCS24 @OncoAlert	Neutral	3,757
Yara Abdou @YAbdouMD	OlympiA: Updated analysis at median fu of 6.1 years (max 9.6 years) Olaparib continues to demonstrate clinically meaningful ⬆️ in IDFS, DDFS and OS in pts with gBRCAm, high risk, HER2- BC across all subgroups ⛔️no increased risk of MDS or…	Neutral	3,748
Elisa Agostinetto @ElisaAgostinett	At #SABCS24 GS1 Survival outcomes in OLYMPIA 10 years after first-patient in (median F-up 6.1 years) Confirmed benefit of adjuvant olaparib in IDFS, DDFS, and OS @OncoAlert	Neutral	2,591
Eleonora Teplinsky, MD @drteplinsky	OlympiA Update: 🔸 At a median f/u 6.1 years: 6 yr IDFS rate 9.4% absolute benefit for olaparib HR 0.65 ⬇️ also in DDFS (7.8% absolute benefit) and OS (4.4% absolute benefit) 🔸 Consistent across all subgroups 🤰Pregnancy data similar bet…	Neutral	2,163
Luca Arecco, MD @Lucarecco	Updated results from #OlympiA trial presented by @judygarber5 in GS1 at #SABCS24 Maintained benefit of adjuvant Olaparib in pts harboring BRCA PV at high risk of recurrence: + 4.4% OS + 7.8% DDFS + 9.4% iDFS ⬇️ 2nd primary cancers in Olap…	Neutral	1,909
Matteo Lambertini, MD PhD @matteolambe	Presented at #SABCS24 updated data from the #olympiA trial showing major benefit of adjuvant #olaparib for #BRCA carriers with high-risk early #BreastCancer @OncoAlert @SABCSSanAntonio @BIGxResearch @UTHealthSA	Neutral	1,864
Oncology Brothers @OncBrothers	2. #OlympiA: Update, Ph III, #Olaparib in mBRCA HER2 -ve, EBC, high-risk s/p local Rx + neo or adj chemo, at 6yrs: - ⬆️ iDFS by 9.4% & DDFS by 7.8% - ⬆️ mOS by 4.4% (87.5% vs 83.2%), HR: 0.72 - Remains the current SoC in this pt populatio…	Neutral	1,653
Kazuki Nozawa, MD @kazuki_nozawa	OlympiA long term follow up data showed clinically meaningful results in IDFS, DDFS, OS. #SABCS24	Neutral	566
Elisabetta Bonzano MD, PhD @to_be_elizabeth	📌 OlympiA: A phase 3, Multicenter, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib after (Neo)Adjuvant Chemotherapy in Patients w/ Germline BRCA1 & BRCA2 Pathogenic Variants & High-Risk HER2-Negative Primary Breast Cancer: Longer …	Neutral	566
Erika Hamilton, MD @ErikaHamilton9	presents OlympiA updated 10 yr data re: olaparib in adj #bcsm Median f/u over 6 years now iDFS 9.4% improved BOTH HR+ and TNBC got benefit DDFS 7.8% improved OS improved by 4.4% #SABCS24 #bcsm @SABCSSanAntonio	Neutral	389
Yakup Ergün @dr_yakupergun	In patients using olaparib who have not undergone salpingo-oophorectomy, the risk of newly diagnosed ovarian cancer appears to be lower. Could olaparib have a protective effect?	Neutral	143
Gustavo Bretas @golbretas	📢 OlympiA Trial Updates at #SABCS24: ⏳ 6.1 years median follow-up (max. 9.6 years): 💊 12 months of adjuvant olaparib continues to show meaningful improvements in IDFS, DDFS, and OS for patients with gBRCAm & high-risk HER2-negative breast …	Neutral	108

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Trial 2 · NCT05498155

What do oncologists think of the OlympiaN trial (LYNPARZA®)?

OlympiaN — Neoadjuvant, chemotherapy-free olaparib +/- durvalumab in gBRCAm, ER-negative/low, HER2-negative early-stage breast cancer (INVESTIGATIONAL)

INVESTIGATIONAL · neoadjuvant BRCAm early BCInvestigational. OlympiaN is a phase 2 study of neoadjuvant, chemotherapy-free olaparib — alone or with durvalumab — in germline BRCA-mutated, ER-negative/low, HER2-negative early (stage I-II) breast cancer. This neoadjuvant use is not FDA-approved. Presented at SABCS 2025.

Physicians are broadly favorable, with real nuance on OlympiaN: 40% of 5 verified physician voices positive, 20% nuanced (praising the result while flagging a caveat), 40% neutral, 0% critical.

40%

20%

40%

Positive 40% Nuanced 20% Neutral 40% Critical 0%

Denominator: 5 distinct verified physician voices across 6 oncologist posts, 2025-12-12 to 2026-01-04. Sponsor: AstraZeneca (study D931CC00001; PI Nadine Tung, Beth Israel Deaconess / DFCI)

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT05498155

Physician voices — verbatim

Representative positive voice

Truly remarkable results😍 In stage I–II BRCA-associated TNBC, a chemotherapy-free regimen achieving pCR rates of 60–80%‼️ #SABCS25

Yakup Ergün

@dr_yakupergun

Representative nuanced voice

OlympiaN: 4-6 neoadjuvant cycles of olaparib +/- durvalumab led to a high pCR rate (60-80%) among BRCAmut patients with stage I-IIA TNBC. Very appealing approach for patients with low clinical risk, warranting validation in a larger sample size! #SABCS25

Paolo Tarantino

@PTarantinoMD

Full physician voice list (5)

Physician	Comment (verbatim)	Sentiment	Impressions
Paolo Tarantino @PTarantinoMD	OlympiaN: 4-6 neoadjuvant cycles of olaparib +/- durvalumab led to a high pCR rate (60-80%) among BRCAmut patients with stage I-IIA TNBC. Very appealing approach for patients with low clinical risk, warranting validation in a larger sample …	Nuanced	12,506
Oncology Brothers @OncBrothers	4 studies that we touched on during Triple Negative #BreastCancer highlights 🗣️ from #SABCS25 w/ @Dr_RShatsky: ✅ #RJBC1501 (PhIII) ✅ #CITRINE (PhIII) ✅ #TBCRC056 (PhII) ✅ #OlympiaN (PhII) When do you consider carboplatin if not used in n…	Neutral	5,981
Sara Tolaney @stolaney1	OlympiaN study by Nadine Tung Preop Olaparib alone or with durvalumab in pts w/ BRCAm and ER-neg or low, HER2-neg Cohort A: olaparib (T1bc/N0) pCR 68% (RCB 0/1 72%) Cohort B: olaparib + durva (cT2N0) pCR 80% (RCB 0/1 84%) @DFCI_BreastOnc…	Neutral	2,870
Yakup Ergün @dr_yakupergun	Truly remarkable results😍 In stage I–II BRCA-associated TNBC, a chemotherapy-free regimen achieving pCR rates of 60–80%‼️ #SABCS25	Positive	473
Abi Siva MD @AbiSivaMD	Impressive results from OlympiaN at #SABCS25 Makes you wonder how many more patients we need before this is ready to be considered standard of care. #BRCA @ASCO @OncBrothers @PTarantinoMD	Positive	234

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Regulatory

LYNPARZA® — FDA status

FDA APPROVEDLYNPARZA® (olaparib) is an FDA-approved PARP inhibitor used across several cancers — including germline BRCA-mutated, HER2-negative breast cancer (both high-risk early and metastatic disease), BRCA- and HRR-mutated advanced prostate cancer, BRCA-mutated advanced ovarian cancer and ovarian-cancer maintenance, and BRCA-mutated metastatic pancreatic cancer. For the full, current list of FDA indications and prescribing information, see lynparza.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.

Frequently Asked

LYNPARZA® sentiment — FAQ

OlympiA

What do oncologists think of the OlympiA trial (LYNPARZA®)?

Across 13 verified physician voices in KOL Pulse's index for OlympiA, 0% expressed positive sentiment, 0% were nuanced (praising the result while flagging a caveat), 100% were neutral, and 0% were critical. Positive voices highlight the sustained invasive- and distant-disease-free-survival and overall-survival benefit of one year of adjuvant olaparib on long-term follow-up, and the move of a PARP inhibitor into the curative-intent adjuvant setting; nuanced and critical voices flag long-term tolerability, patient selection and germline testing access, and open questions such as PALB2 and combination/sequencing with immunotherapy.

Where can I find the OlympiA trial data for LYNPARZA® (olaparib)?

OlympiA is registered as NCT02032823 and studied LYNPARZA® (olaparib) in Adjuvant gBRCAm, HER2-negative, high-risk early breast cancer (1 year of olaparib). KOL Pulse's OlympiA trial profile is coming soon.

OlympiaN

What do oncologists think of the OlympiaN trial (LYNPARZA®)?

Across 5 verified physician voices in KOL Pulse's index for OlympiaN, 40% expressed positive sentiment, 20% were nuanced (praising the result while flagging a caveat), 40% were neutral, and 0% were critical. Positive voices highlight the high pathologic-complete-response rates achieved with a chemotherapy-free neoadjuvant PARP-inhibitor regimen in early BRCA-mutated breast cancer, and the prospect of de-escalating chemotherapy; nuanced and critical voices flag the small, non-randomized phase 2 design, the immaturity of event-free and survival outcomes, and how many patients are needed before this is practice-ready.

Where can I find the OlympiaN trial data for LYNPARZA® (olaparib)?

OlympiaN is registered as NCT05498155 and studied LYNPARZA® (olaparib) in Neoadjuvant, chemotherapy-free olaparib +/- durvalumab in gBRCAm, ER-negative/low, HER2-negative early-stage breast cancer (INVESTIGATIONAL). KOL Pulse's OlympiaN trial profile is coming soon.

Regulatory

Is LYNPARZA® (olaparib) FDA approved?

LYNPARZA® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.

Methodology

How this index is built

KOL Pulse indexes verbatim posts from verified oncology physicians and rolls sentiment up per clinical trial. Each physician is counted once per trial, at their highest-reach post. Sentiment is classified from the verbatim text (positive / nuanced / neutral / critical), where "nuanced" marks a voice that praises the result while flagging a substantive caveat (immature overall survival, toxicity, or trial-design/selection concerns). Institutional, media, finance, and non-physician accounts are excluded from the denominator. Quotes are reproduced verbatim and attributed to the physician's public post. KOL Pulse organizes this page by clinical trial — the maintainable unit — and links out to the manufacturer's brand site and the FDA label for the full indication list, which the manufacturer owns and updates. Trial efficacy figures are held for medical-expert verification before publication. This page reports the physician conversation; it is not medical advice and does not endorse any product.